Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 01 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.25 Insider Own0.00% Shs Outstand128.39M Perf Week7.88%
Market Cap509.71M Forward P/E- EPS next Y-0.02 Insider Trans- Shs Float128.39M Perf Month4.75%
Income-31.26M PEG- EPS next Q- Inst Own66.98% Short Float2.16% Perf Quarter108.95%
Sales8.79M P/S57.99 EPS this Y33.99% Inst Trans-7.45% Short Ratio1.72 Perf Half Y183.57%
Book/sh0.57 P/B6.94 EPS next Y61.98% ROA-26.75% Short Interest2.78M Perf Year356.32%
Cash/sh0.42 P/C9.52 EPS next 5Y- ROE-39.59% 52W Range0.69 - 4.36 Perf YTD71.86%
Dividend Est.- P/FCF- EPS past 5Y37.31% ROI-39.42% 52W High-8.94% Beta0.80
Dividend TTM- Quick Ratio3.11 Sales past 5Y-25.00% Gross Margin63.56% 52W Low477.03% ATR (14)0.27
Dividend Ex-Date- Current Ratio3.11 EPS Y/Y TTM-21.83% Oper. Margin-469.88% RSI (14)61.95 Volatility7.12% 7.35%
Employees36 Debt/Eq0.16 Sales Y/Y TTM-100.00% Profit Margin-355.64% Recom1.00 Target Price5.00
Option/ShortYes / Yes LT Debt/Eq0.08 EPS Q/Q48.97% Payout- Rel Volume1.54 Prev Close3.80
Sales Surprise- EPS Surprise3.10% Sales Q/Q- EarningsSep 07 BMO Avg Volume1.62M Price3.97
SMA204.82% SMA5024.23% SMA200106.40% Trades Volume2,495,207 Change4.47%
Date Action Analyst Rating Change Price Target Change
Oct-13-23Resumed BTIG Research Buy $4
Aug-12-22Initiated Cantor Fitzgerald Overweight $4
May-05-21Initiated BTIG Research Buy $10
Apr-05-21Initiated Needham Buy $10
Feb-16-24 03:57AM
Jan-08-24 07:00AM
Dec-19-23 11:21AM
Nov-03-23 11:43AM
Oct-23-23 04:01PM
04:30PM Loading…
Oct-14-23 04:30PM
Oct-09-23 08:00AM
Sep-21-23 07:00AM
Sep-07-23 07:30AM
Aug-10-23 11:04PM
Aug-04-23 08:12AM
Jul-07-23 07:46AM
Jul-06-23 08:00AM
May-31-23 07:00AM
May-23-23 01:43PM
12:46PM Loading…
May-08-23 12:46PM
May-05-23 04:06PM
Apr-21-23 12:00PM
Apr-13-23 08:00AM
Mar-28-23 04:30PM
Mar-21-23 06:30AM
Feb-08-23 07:00AM
Jan-10-23 05:35AM
Nov-15-22 09:35AM
Nov-08-22 07:00AM
Nov-02-22 04:01PM
Oct-28-22 07:00AM
Oct-24-22 04:30PM
Oct-21-22 07:00AM
Oct-18-22 11:58AM
07:00AM Loading…
Oct-17-22 07:00AM
Oct-03-22 05:00PM
Sep-28-22 09:21AM
Sep-26-22 07:00AM
Sep-14-22 09:00AM
Sep-12-22 08:00AM
Sep-09-22 08:22PM
Aug-31-22 07:00AM
Aug-22-22 04:00AM
Jul-05-22 04:01PM
Jun-21-22 08:30AM
Jun-20-22 10:36AM
Jun-17-22 05:30PM
Jun-02-22 08:00AM
May-26-22 05:05PM
May-17-22 08:00AM
May-09-22 07:45AM
May-06-22 05:12PM
Apr-22-22 09:35AM
Apr-06-22 08:00AM
Mar-31-22 04:01PM
Mar-03-22 08:30AM
Mar-01-22 08:00AM
Feb-10-22 08:00AM
Jan-12-22 01:59PM
Dec-29-21 01:19AM
Dec-22-21 07:00AM
Dec-17-21 12:38AM
Dec-15-21 09:38PM
Dec-13-21 07:00AM
Dec-10-21 09:38PM
Nov-30-21 07:00AM
Nov-09-21 08:00AM
Nov-04-21 09:00AM
Oct-31-21 10:30AM
Oct-26-21 10:26AM
Oct-13-21 08:00AM
Oct-01-21 04:31PM
Sep-20-21 08:00AM
Sep-09-21 08:00AM
Aug-02-21 08:00AM
Jul-19-21 07:04PM
Jun-02-21 09:45AM
May-27-21 08:00AM
May-04-21 08:00AM
Apr-30-21 08:00AM
Apr-08-21 08:30AM
Mar-31-21 05:02PM
Feb-25-21 11:33AM
Feb-18-21 07:00AM
Feb-12-21 12:41PM
Feb-10-21 07:00AM
Feb-09-21 04:03PM
Dec-21-20 10:26AM
Dec-18-20 11:15AM
Dec-17-20 04:05PM
Dec-15-20 01:00PM
Dec-07-20 10:59PM
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.